Blog - Page 854 of 5707 - QualityStocks

MondayNov 07, 2022 10:11 am

QualityStocksNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Featured in Investment Research Report

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, was featured in a recent report published by Zacks Small-Cap Research. In the report, Zacks valued BVXV at $12.00/ADS. The publication reads, “On August 25, 2022, BiondVax Pharmaceuticals Ltd. (BVXV) announced financial results for the second quarter of 2022 and provided a business update. The COVID-19 NanoAb program is proceeding on schedule, with an inhalation proof-of-concept study with the anti-SARS-CoV-2 NanoAb in COVID-19 infected animals expected to begin by the end of 2022. Based on…

MondayNov 07, 2022 9:45 am

New Pharmaceutical Subsidiary Geared to Aid Odyssey Health, Inc. (ODYY) Development of Novel Solutions for Brain Related Medical Treatments

Odyssey Health Inc. is a medical product developer with a mission of filling unmet needs when it comes to acute emergencies involving patients’ central nervous systems The company recently announced the formation of a wholly owned subsidiary to help Odyssey develop its products as they move through the regulatory process Odyssey’s solutions include a breath-powered intranasal delivery mechanism and synthetic neurosteroids designed to provide rapid-response treatment for patients with concussions and a highly fatal pediatric neurological disease Odyssey Health also is developing solutions for heart disease detection, obstructed-airway choking and nerve agent exposure The concussion therapeutic solution recently completed Phase…

MondayNov 07, 2022 9:00 am

Flora Growth Corp. (NASDAQ: FLGC) Agreement to Acquire Multi-national Cannabis Operator Positions Company for New Strategic Growth in Europe

Flora Growth is a cannabis cultivator and international brand developer with a strong base of operations at its licensed facility in northern Colombia Flora recently announced its plans to acquire multi-national operator Franchise Global Health (“FGH”), the latest of its strategic acquisitions designed to boost revenues and expand Flora’s international footprint FGH is focused on the German market, where its subsidiary was the first company to sell cannabis Germany is in turn expected to provide the companies a launching pad for success in Europe, where opportunity is defined by the fact that currently Germany provides 75 to 80 percent of…

FridayNov 04, 2022 3:21 pm

QualityStocksNewsBreaks – Reklaim Ltd.’s (TSX.V: MYID) (OTCQB: MYIDF) Revolutionary System Enables Consumers to Take Control of Their Data

Reklaim (TSX.V: MYID) (OTCQB: MYIDF) is the destination for consumers to access and reclaim their data. “Reklaim’s creation was a by-product of the ongoing evolution of data privacy and its impact on consumers and companies. The company’s revolutionary system allows consumers to log in to their platform and confirm their identity, unlocking data collected on them that has been bought and sold for years without their explicit consent. At that point, consumers can take control of their data and, if they choose, receive compensation for its use. With consent secured, Reklaim offers the data to Fortune 500 brands, platforms and…

FridayNov 04, 2022 1:57 pm

QualityStocksNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Increasing Access to Safe, Legal CBD and THC to Global Consumers

Flora Growth Corp. (NASDAQ: FLGC) is a cannabis cultivator, brand manufacturer and global distributor. “The Canadian company with a productive base of operations in Colombia’s fertile greenbelt is licensed to cultivate cannabis on a 100-hectare (about 247-acre) farming facility and then deliver its product to its GMP-certified processing facility in the nation’s capital, where beauty, phytotherapeutic and nutraceutical products are prepared for market…. Flora’s brand division is focused on developing plant-based consumer products, such as cannabinoid-infused juices, gummies, topicals, inhalables, and skin care. But the company also prioritizes the manufacture of ‘cannabinoid-derived medical formulations that can be sold domestically and…

FridayNov 04, 2022 1:38 pm

QualityStocksNewsBreaks – FuelPositive Corp. (TSX.V: NHHH) (OTCQB: NHHHF) Empowering Farmers to Reduce Over-Reliance on Global Supply Chains

FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF), a growth-stage enterprise focused on opportunities relating to energy-efficient technology and sustainability, is pushing for the production of green ammonia that consumers can afford while, at the same time, addressing issues that are currently being felt on a global scale. “According to FuelPositive, a sure way to help guarantee food security and reduce the over-reliance on global supply chains is to empower farmers. This, it argues, starts with disrupting the fertilizer sector, specifically the traditional ammonia sector. Its onsite, containerized green ammonia production system allows farmers to produce their own nitrogen fertilizer on their farms,…

FridayNov 04, 2022 1:00 pm

QualityStocksNewsBreaks – Golden Matrix Group Inc. (NASDAQ: GMGI) Announces Full Acquisition of Interest in RKings Competitions

Golden Matrix Group (NASDAQ: GMGI), a developer and licensor of gaming platforms, systems and gaming content, has acquired the remaining 20% interest in RKings Competitions; the company now owns a total of 165,444 restricted shares of GMGI’s common stock payable to the two former owners of RKings. Company officials announced the transaction, which makes RKings a wholly owned entity of Golden Matrix, one which the company anticipates will grow quickly in several regulated jurisdictions, including Great Britain and Mexico. The company plans to expand the tournament platform into other Latin American markets in the next few years. In addition, Golden Matrix…

FridayNov 04, 2022 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Zero Adverse Effects from Successful HYPER-H21-4 Study of DehydraTECH(TM)-CBD for High Blood Pressure

The CDC reported more than 670,000 annual deaths in the United States with high blood pressure as a primary or contributing cause Lexaria's patented DehydraTECH(TM) technology has been shown, through HYPER-H21-4 study, to decrease high blood pressure in subjects through DehydraTECH-CBD-enabled dosing The global antihypertension drug market was valued at over $22.5 billion in revenue in 2018 and is expected to grow at a CAGR of 3.1%, resulting in a market of over $28.7 billion by 2026 In the United States, uncontrolled high blood pressure is common among adults – with only one in four having the condition under control.…

FridayNov 04, 2022 10:04 am

QualityStocksNewsBreaks – CubCrafters, Missionary Pilot Partner to Fly Life-Saving Missions in Mexico

CubCrafters, the leading designer and manufacturer of light-sport, experimental and Part 23-certified backcountry aircraft, has built aircraft that has been flown around the world for many reasons. Brent Dodd and his CubCrafters Carbon Cub EX are flying for what may be the most important reason of all — to save lives. Serving in Mexico for the United Indian Mission, Dodd is the organization’s director of flight operations; he also serves as an airframe and power-plant mechanic and is the pilot of the Carbon Cub, which has been slightly modified for its life-saving work. According to Dodd, who was featured in a…

FridayNov 04, 2022 9:45 am

Silo Pharma Inc. (NASDAQ: SILO) Extends Columbia University Agreement to Continue Research for Therapeutics to Treat Alzheimer’s Disease

Silo recently extended Columbia University agreement to continue research for novel therapeutics to treat Alzheimer’s disease and stress-induced anxiety disorder Preclinical studies demonstrate Silo’s jointly-developed Z-pod(TM) delivery technology holds and distributes therapeutics in a time-released manner to potentially provide targeted delivery Additional treatment research includes funding for the UCSF Translational Psychedelic Program to study effects of psilocybin on various inflammatory conditions Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company, fuses traditional therapeutics with psychedelic medicine to treat numerous underserved conditions, including fibromyalgia, post-traumatic stress disorder, and Alzheimer’s disease. Through a joint partnership agreement with Columbia University, researchers are currently…

Site Search

Company Search